Rockwell Medical, Inc. (NASDAQ: RMTI) Starts Presentation at the 2017 Disruptive Growth Company Showcase
Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company with a focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company provides innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic, the company’s anemia drug, is FDA approved for iron replacement and maintenance of hemoglobin in hemodialysis patients. The company also has an FDA approved generic drug, Calcitriol, for treating secondary hyperparathyroidism in dialysis patients. Rockwell also manufactures high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. For more information, visit the company’s website at www.rockwellmed.com. About NetworkNewsWire NetworkNewsWire…







